Table 1.
Baseline characteristics of the study participants (before PSM)
| Variables | Total (n = 90) | Unmatched cohort | p | |
|---|---|---|---|---|
| cTACE (n = 58) | cTACE+MWA (n = 32) | |||
| Age, mean ± SD | 57.9 ± 10.4 | 57.8 ± 10.6 | 58.1 ± 10.2 | 0.886 |
| Sex, n (%) | 0.74 | |||
| Female | 11 (12.2) | 8 (13.8) | 3 (9.4) | |
| Male | 79 (87.8) | 50 (86.2) | 29 (90.6) | |
| HBV, n (%) | 0.089 | |||
| No | 22 (24.4) | 18 (31) | 4 (12.5) | |
| Yes | 68 (75.6) | 40 (69) | 28 (87.5) | |
| HCV, n (%) | 0.343 | |||
| No | 85 (94.4) | 56 (96.6) | 29 (90.6) | |
| Yes | 5 ( 5.6) | 2 (3.4) | 3 (9.4) | |
| AFP, n (%) | 0.361 | |||
| <200ng/ml | 63 (70.0) | 43 (74.1) | 20 (62.5) | |
| ≥200ng/ml | 27 (30.0) | 15 (25.9) | 12 (37.5) | |
| CP, n (%) | 1 | |||
| A | 81 (90.0) | 52 (89.7) | 29 (90.6) | |
| B | 9 (10.0) | 6 (10.3) | 3 (9.4) | |
| Tumor size, median (IQR) | 3.4 (3.0, 4.3) | 3.3 (3.0, 4.0) | 4.0 (3.2, 4.5) | 0.009 |
| Portal hypertension, n (%) | 0.157 | |||
| No | 43 (47.8) | 24 (41.4) | 19 (59.4) | |
| Yes | 47 (52.2) | 34 (58.6) | 13 (40.6) | |
| PLT (×109/L), median | 99.0 (69.2, 149.8) | 86.5 (67.2, 145.5) | 113.5 (81.2, 151.5) | 0.228 |
| TBIL (μmol/L), median (IQR) | 14.2 (9.1, 18.1) | 14.5 (9.4, 19.0) | 12.2 (8.3, 16.7) | 0.1 |
| CRE (μmol/L), median (IQR) | 65.0 (59.0, 70.0) | 65.0 (59.2, 70.8) | 64.0 (59.0, 68.5) | 0.723 |
| INR, median (IQR) | 1.1 (1.1, 1.2) | 1.1 (1.1, 1.2) | 1.1 (1.0, 1.1) | 0.033 |
Notes: data presented are mean±SD, median (Q1–Q3), and N (%)
Abbreviations: HBV hepatic B virus, HCV hepatic C virus, AFP alpha-fetoprotein, CP Child-Pugh Classification, PLT platelet, TBIL total bilirubin, CRE creatinine, INR prothrombin time-international normalized ratio